PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
19 Settembre 2023 - 7:00AM
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella
pneumoniae, a new resistant and aggressive bacterial target
PHAXIAM Therapeutics extends its phage
portfolio to Klebsiella
pneumoniae, a new resistant and aggressive
bacterial target
- Klebsiella
pneumoniae is responsible for
severe infections and
stands out for its high
resistance to
antibiotics
- PHAXIAM's
anti-Klebsiella pneumoniae
phages to enter
pre-clinical development to assess their efficacy in
lung, blood
and urinary tract infections, in addition to
the three major targets already developed
(S. aureus, P. aeruginosa, E.
coli)
Lyon (France) and
Cambridge (MA, US), September
19, 2023
– 07:00 a.m. CEST
– PHAXIAM Therapeutics (Nasdaq
& Euronext: FR0011471135), today announces the
launch of a new preclinical development targeting a strong
antimicrobial-resistant
bacteria, Klebsiella
pneumonia.
Klebsiella pneumoniae (K. pneumoniae) causes a
wide range of infections, including pneumonia, urinary tract
infections, bacteremia and liver abscesses, and mainly infects
immunocompromised people. However, the emergence and spread of
hypervirulent and multi-resistant strains of this bacterium have
recently extended its potential targets to people with no health
problems.
In Western countries, we estimate that between
3% and 5% of pneumonias are linked to an infection caused by K.
pneumoniae. Worldwide, K. pneumoniae is responsible for 11.8% of
hospital-acquired pneumonia. In high-risk patients (alcoholics and
septicemics), the mortality rate associated with this kind of
infection is between 50 and 100%1. The incidence of K. pneumoniae
resistances is evaluated between 90-100,000 patients in the US and
EU52, mainly in Urinary Tract infections and Respiratory Tract
infections.
Recent studies in Europe and the United
States3,4 also revealed the existence of K. pneumoniae strains with
an exceptionally high level of antimicrobial resistance, making
them even more difficult to treat. The results of these studies
demonstrated a worrying trend among the samples collected, which
may even be resistant to enzyme-inhibiting antibiotics that have
recently been developed but have not yet been marketed. This level
of antimicrobial resistance in K. pneumoniae strains had never been
observed before.
Selected phages will be evaluated on a wide
range of infections in which PHAXIAM already benefits from
considerable expertise, such as lung, blood and urinary tract
infections. This will enable the Company to capitalize on
preclinical models validated with its three historical phage
families, mutualize certain developments within the same indication
and accelerate the progression to clinical phases.
Thibaut du Fayet, Chief
Executive Officer of PHAXIAM
Therapeutics, stated: “With the launch of this new
program, PHAXIAM Therapeutics deploys its strategy in line with the
plan presented during the merger, and reaffirms its position at the
forefront of the fight against antimicrobial resistance. K.
pneumoniae bacteria represents a new target with a high medical
need, affecting a large population worldwide, and for which
antibiotics offer only a limited therapeutic solution. Our
anti-Klebsiella phages will thus complement an already extended
phage portfolio for the clinical indications we are targeting, and
reinforce our ability to efficiently address a broad spectrum of
resistant bacterial infections.”
About PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company
developing innovative treatments for resistant bacterial
infections, which are responsible for many serious infections. The
company is building on an innovative approach based on the use of
phages, natural bacterial-killing viruses. PHAXIAM is developing a
portfolio of phages targeting 3 of the most resistant and dangerous
bacteria, which together account for more than two-thirds of
resistant hospital-acquired infections: Staphylococcus aureus,
Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Nasdaq Global Select
Market in the United States (ticker: PHXM – to be modified to a new
symbol) and on the Euronext regulated market in Paris (ISIN code:
FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare,
CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable,
EnterNext PEA-PME 150 and Next Biotech indexes.
For more information, please visit www.phaxiam.com
Contacts
PHAXIAMEric SoyerDeputy CEO, COO
& CFO+33 4 78 74 44 38 investors@phaxiam.com |
NewCap Mathilde Bohin /
Dušan OrešanskýInvestor
RelationsArthur RouilléMedia Relations +33 1 44 71
94 94 phaxiam@newcap.eu |
1 John V. Ashurst; Adam Dawson ET AL., 2022.2 Five main European
countries: France, Germany, UK, Spain & Italy3 Highly
multidrug-resistant Gram-negative bacterial infections in war
victims in Ukraine, 2022; The Lancet Infectious Diseases4 NIH
investigates multidrug-resistant bacterium emerging in community
settings; National Institutes of Health (NIH)
- PR_PHAXIAM_Klebsiella_EN_19092023
Grafico Azioni Phaxiam Therapeutics (LSE:0QSS)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Phaxiam Therapeutics (LSE:0QSS)
Storico
Da Mag 2023 a Mag 2024